

CLAIMS

1. An agent for ameliorating low vasopressin level, which comprises, as an active ingredient, a substance capable of inhibiting the binding between parathyroid hormone-related peptide (PTHrP) and a receptor thereof.
2. The agent according to claim 1, wherein the substance is an antagonist against a PTHrP receptor.
3. The agent according to claim 1, wherein the substance is an anti-PTHrP antibody.
4. The agent according to claim 1, wherein the substance is a fragment of an anti-PTHrP antibody and/or a modified form of the fragment.
5. The agent according to claim 3 or 4, wherein the antibody is a humanized or chimeric antibody.
6. The agent according to claim 5, wherein the humanized antibody is humanized #23-57-137-1 antibody.
7. The agent according to claim 3 or 4, wherein the antibody is a monoclonal antibody.
8. The agent according to any one of claims 1 to 7, wherein low vasopressin level results from cancer.
9. An agent for ameliorating a symptom caused by a decrease in vasopressin level, which comprises, as an active ingredient, a substance capable of inhibiting the

binding between parathyroid hormone-related peptide (PTHrP) and a receptor thereof.

10. The agent according to claim 9, wherein the decrease in vasopressin level results from cancer.

11. The agent according to claim 9 or 10, wherein the symptom caused by a decrease in vasopressin level is at least one symptom selected from the group consisting of polyuria, dehydration, mouth dryness and hyperosmolarity.

12. An agent for ameliorating hyperosmolarity, which comprises, as an active ingredient, a substance capable of inhibiting the binding between parathyroid hormone-related peptide (PTHrP) and a receptor thereof.

13. The agent according to claim 12, wherein the hyperosmolarity is associated with vomiting, diarrhea, fever, sweating, diabetes insipidus, or diabetes.

14. An agent for ameliorating dehydration, which comprises, as an active ingredient, a substance capable of inhibiting the binding between parathyroid hormone-related peptide (PTHrP) and a receptor thereof.

15. The agent according to claim 14, wherein the dehydration is associated with vomiting, diarrhea, fever, sweating, diabetes insipidus, or diabetes.